Contineum Therapeutics (CTNM) Cash & Equivalents (2023 - 2025)
Historic Cash & Equivalents for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $42.6 million.
- Contineum Therapeutics' Cash & Equivalents rose 426.01% to $42.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 426.01%. This contributed to the annual value of $21.9 million for FY2024, which is 4133.07% up from last year.
- Per Contineum Therapeutics' latest filing, its Cash & Equivalents stood at $42.6 million for Q3 2025, which was up 426.01% from $20.8 million recorded in Q2 2025.
- In the past 5 years, Contineum Therapeutics' Cash & Equivalents ranged from a high of $77.2 million in Q2 2024 and a low of $15.5 million during Q4 2023
- Over the past 3 years, Contineum Therapeutics' median Cash & Equivalents value was $22.2 million (recorded in 2024), while the average stood at $32.2 million.
- In the last 5 years, Contineum Therapeutics' Cash & Equivalents surged by 4133.07% in 2024 and then crashed by 7308.82% in 2025.
- Quarter analysis of 3 years shows Contineum Therapeutics' Cash & Equivalents stood at $15.5 million in 2023, then skyrocketed by 41.33% to $21.9 million in 2024, then soared by 94.29% to $42.6 million in 2025.
- Its Cash & Equivalents was $42.6 million in Q3 2025, compared to $20.8 million in Q2 2025 and $22.5 million in Q1 2025.